var data={"title":"Iron sucrose: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iron sucrose: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6404?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iron-sucrose-drug-information\" class=\"drug drug_general\">see &quot;Iron sucrose: Drug information&quot;</a> and <a href=\"topic.htm?path=iron-sucrose-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iron sucrose: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184604\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Venofer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184605\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Venofer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020337\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Iron Salt, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Mineral, Parenteral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15852436\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering</b>; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or under-dosing. Doses are expressed as mg of <b>elemental iron</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia of prematurity:</b> Limited data available; dosing regimens variable: IV: 1 mg/kg/<b>day</b> infused over 2 hours or 6 mg/kg/dose once weekly infused over 1 hour; daily dosing based on results of a small comparative trial of 29 premature neonates (GA &lt;31 weeks) who received oral iron (n=9), oral iron plus epoeitin (n=10), or 2 mg/kg/day for 3 weeks of iron sucrose plus epoeitin (n=10, mean age: 23.3 &plusmn; 2.9 days; mean weight: 1,266 &plusmn; 81 g); higher reticulocyte counts and fewer transfusions were observed in infants who received iron sucrose compared oral treatment; due to potential oxidative injury risk in smaller, less stable premature neonates, the authors suggest that lower doses of 1 mg/kg/day should be considered (Pollock 2001; Pollock 2001a). Weekly dosing based on a small comparative trial of 42 neonates (GA &lt;33 weeks, birthweight &lt;1,500 g) who received both epoeitin and oral iron (n=21) or 6 mg/kg/dose once weekly of iron sucrose (n=21, mean age: 26.4 &plusmn; 8.4 days and mean weight of 1,292 &plusmn; 173.3 g); hematologic response was similar in both groups; however, iron sucrose was not associated with a decline in ferritin suggesting improved iron storage compared to oral (Meyer 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020366\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=iron-sucrose-drug-information\" class=\"drug drug_general\">see &quot;Iron sucrose: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering</b>; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or underdosing. Doses are expressed as mg of <b>elemental iron</b>. <b>Note:</b> Per National Kidney Foundation DOQI Guidelines, initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent. See Reference Range for target levels. There is insufficient evidence to recommend IV iron if ferritin level &gt;500 ng/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency anemia in CKD:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Repletion treatment:</i> Limited data available: Children &ge;2 years and Adolescents &lt;15 years: IV: 1 mg/kg/dialysis; dosing based on a dose-finding trial in 14 pediatric patients and successfully increased ferritin therapeutic levels; iron overload (serum ferritin &gt;400 ng/mL) was reported with the higher dose used in the study (3 mg/kg/dialysis) (Leijn 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance therapy:</i> Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis-dependent CKD: IV: 0.5 mg/kg/dose (maximum dose: 100 mg) every 2 weeks for 12 weeks (6 doses); may repeat if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis-dependent CKD; concurrent erythropoietin therapy: IV: 0.5 mg/kg/dose (maximum dose: 100 mg) every 4 weeks for 12 weeks (3 doses); may repeat if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nondialysis-dependent CKD; concurrent erythropoietin therapy: IV: 0.5 mg/kg/dose (maximum dose: 100 mg) every 4 weeks for 12 weeks (3 doses); may repeat if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency anemia, nonrenal causes; treatment in patients refractory to oral therapy (eg, long-term TPN, GI malabsorption):</b> Limited data available (Norman 2011; Pinsk 2008): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Calculate Iron Deficit: Total replacement dose (mg of iron) = 0.6 x weight (kg) x [100 - (actual Hgb /12 x 100)]; <b>Note:</b> In this equation, 12 is the desired target Hgb concentration; in some patients, a different target may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose: IV: 5 to 7 mg/kg/dose; maximum initial dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: IV: 5 to 7 mg/kg/dose every 1 to 7 days until total replacement dose achieved; maximum single dose: 300 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:<b> Iron deficiency anemia in CKD:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis-dependent CKD: 100 mg administered during consecutive dialysis sessions to a cumulative total dose of 1,000 mg (10 doses); may repeat treatment if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis-dependent CKD: Two infusions of 300 mg administered 14 days apart, followed by a single 400 mg infusion 14 days later (total cumulative dose of 1,000 mg in 3 divided doses); may repeat treatment if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nonhemodialysis-dependent CKD: 200 mg administered on 5 different occasions within a 14-day period; cumulative total dose: 1,000 mg in 14-day period. <b>Note:</b> Dosage has also been administered as two infusions of 500 mg in a maximum of 250 mL normal saline infused over 3.5 to 4 hours on day 1 and day 14 (limited experience); may repeat treatment if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Nondialyzable. There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184587\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Venofer: 20 mg/mL (2.5 mL, 5 mL, 10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184573\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963477\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=iron-sucrose-drug-information\" class=\"drug drug_general\">see &quot;Iron sucrose: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Strength of iron sucrose is expressed as elemental iron.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020369\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: May administer IV; not for IM use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric patients:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates: Infusion: Infuse over at least 1 to 2 hours (Meyer 1996; Pollak 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Dependent upon indication:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CKD treatment of iron deficiency anemia:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Slow IV injection: Administer undiluted over 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infusion: Dilute and infuse over 5 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nonrenal treatment of iron deficiency anemia: One trial reported infusion of a diluted 1 mg/mL solution at 1 to 1.3 mL/minute (Pinsk 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Others suggest the following recommendations (Norman 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">For doses &le;100 mg, infuse over at least 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">For doses &gt;100 mg and &le;200 mg, infuse over at least 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">For doses &gt;200 mg and &le;300 mg, infuse over at least 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Slow IV injection: May administer doses &le;200 mg undiluted by slow IV injection over 2 to 5 minutes; when administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infusion: Infuse diluted doses &le;200 mg over at least 15 minutes; infuse diluted 300 mg dose over 1.5 hours; infuse diluted 400 mg dose over 2.5 hours; infuse diluted 500 mg dose over 3.5 to 4 hours (limited experience). When administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184600\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials in original carton at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Iron sucrose is stable for 7 days at room temperature (23&deg;C to 27&deg;C [73&deg;F to 81&deg;F]) or under refrigeration (2&deg;C to 6&deg;C [36&deg;F to 43&deg;F]) when undiluted in a plastic syringe or following dilution in normal saline in a plastic syringe (concentration 2 to 10 mg/mL) or for 7 days at room temperature (23&deg;C to 27&deg;C [73&deg;F to 81&deg;F]) following dilution in normal saline in an IV bag (concentration 1 to 2 mg/mL).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020338\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\"> Treatment of iron deficiency anemia in hemodialysis-dependent chronic kidney disease (HDD-CKD) (FDA approved in ages &ge;2 years and adults); treatment of iron deficiency anemia with concurrent erythropoietin therapy in peritoneal dialysis-dependent (PDD) CKD and nondialysis-dependent (NDD) CKD (FDA approved in ages &ge;2 years); treatment of iron deficiency anemia in PDD-CKD and NDD-CKD (FDA approved in adults); has also been used for treatment of nonrenal iron deficiency anemia  and supplementation of iron in patients for which oral therapy is neither effective nor tolerated (eg, long-term TPN)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7897706\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Iron sucrose may be confused with ferumoxytol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184624\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Events are associated with use in adults unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac failure, chest pain, hypertension (less common in children), hypotension (most common in hemodialysis patients; may be related to total dose or rate of administration), peripheral edema, thrombosis (children; arteriovenous fistula</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Gout, hyperglycemia, hypervolemia, hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia, nausea (less common in children), peritonitis (children), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Graft complications</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, muscle cramps (most common in hemodialysis patients), myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, nasal congestion, nasopharyngitis, pharyngitis, sinusitis, upper respiratory tract infection (less common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactic shock, anaphylactoid reaction, angioedema, bradycardia, bronchospasm, circulatory shock, hypersensitivity reaction (including wheezing), loss of consciousness, necrotizing enterocolitis (reported in premature infants; no causal relationship established), seizure, shock, urine discoloration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184593\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to iron sucrose or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for iron is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184577\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Cases of hypersensitivity reactions, including anaphylactic and anaphylactoid reactions (some fatal), have been reported. Monitor patients during and for &ge;30 minutes postadministration; discontinue immediately for signs/symptoms of a hypersensitivity reaction (shock, hypotension, loss of consciousness) or if signs of intolerance occur. Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Significant hypotension has been reported frequently in hemodialysis-dependent patients. Has also been reported in peritoneal dialysis and nondialysis patients. Hypotension may be related to total dose or rate of administration (avoid rapid IV injection), follow recommended guidelines.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Withhold iron in the presence of tissue iron overload; periodic monitoring of hemoglobin, hematocrit, serum ferritin, and transferrin saturation is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26023252\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use parenteral iron products with caution in premature neonates; necrotizing enterocolitis has been reported; however, no causal relationship established. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299545\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184581\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13058&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184583\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184594\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Iron can be detected in the fetus and cord blood; concentrations may be influenced by maternal iron status (IOM 2001). iron-deficiency anemia in a pregnant female may be associated with adverse events, including low birth weight, preterm birth, or increased perinatal mortality (ACOG 95 2008; IOM 2001).</p>\n    <p style=\"text-indent:0em;\">Iron requirements increase during pregnancy. All females should be screened for iron deficiency during pregnancy; if iron-deficiency anemia is present, supplemental iron (in addition to prenatal vitamins) should be administered. Oral preparations are generally sufficient, however parenteral iron therapy may be used in females who cannot tolerate or will not take oral iron, in cases of severe iron deficiency, or when malabsorption is present (ACOG 95 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020371\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hematocrit, hemoglobin, serum ferritin, transferrin, percent transferrin saturation, TIBC; takes about 4 weeks of treatment to see increased serum iron and ferritin, and decreased TIBC. Serum iron concentrations should be drawn &ge;48 hours after last dose (due to rapid increase in values following administration); signs/symptoms of hypersensitivity reactions (during and &ge;30 minutes following infusion); hypotension (following infusion).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1020360\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum iron: All ages: 22 to 184 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total iron binding capacity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 100 to 400 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children, Adolescents, and Adults: 250 to 400 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ferritin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0 to 6 weeks: 0 to 400 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7 weeks to 1 year: 10 to 95 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 9 years: 10 to 60 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 to 18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Male: 10 to 300 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Female: 10 to 70 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chronic kidney disease (CKD): Targets for iron therapy (KDOQI Guidelines, 2007) to maintain Hgb 11 to 12 g/dL:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Nondialysis CKD, hemodialysis, or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Nondialysis (CKD) or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Ferritin &gt;200 ng/mL and TSAT &gt;20% or CHr (content of hemoglobin in reticulocytes) &gt;29 pg/cell</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184576\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose. The released iron increases serum iron concentrations and is incorporated into hemoglobin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184592\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: Peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase within 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Healthy adults: 7.9 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Dissociated into iron and sucrose by the reticuloendothelial system</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Healthy adults: 6 hours; Nondialysis-dependent adolescents: 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Healthy adults: Urine (5%) within 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5275404\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Contains sucrose: 300 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323230\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Venofer Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (5 mL): $60.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184595\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anerrum (TH);</li>\n      <li>Avofer (MY);</li>\n      <li>Dialifer (ID);</li>\n      <li>Encifer (LK, ZW);</li>\n      <li>Femax (PH);</li>\n      <li>Femorum (TH);</li>\n      <li>Feofer (BD);</li>\n      <li>Ferogen (TH);</li>\n      <li>Feromax (ET, QA);</li>\n      <li>Feromin (PH);</li>\n      <li>Ferrofer (TH);</li>\n      <li>Ferrovin (KR);</li>\n      <li>Incros (LK);</li>\n      <li>Maxifer (PH);</li>\n      <li>Medofer (PH);</li>\n      <li>Nefrofer (BD, ID);</li>\n      <li>Rafofer (CL);</li>\n      <li>Rinofer (ID);</li>\n      <li>Sucrox (AR);</li>\n      <li>Venofer (AR, AT, AU, BE, BG, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, ES, FI, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IS, JO, LB, LK, LT, LU, LV, MY, NI, NL, NO, NZ, PA, PE, PK, PL, PT, PY, RO, SE, SG, SI, SK, SV, TH, TR, UY, VE, ZA);</li>\n      <li>Venoferrum (KR);</li>\n      <li>Xenofer (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Crary SE, Hall K, and Buchanan GR, &quot;Intravenous Iron Sucrose for Children With Iron Deficiency Failing to Respond to Oral Iron Therapy,&quot; <i>Pediatr Blood Cancer</i>, 2011, 56(4):615-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/21298748/pubmed\" target=\"_blank\" id=\"21298748\">21298748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target,&quot; <i>Am J Kidney Dis</i>, 2007, 50(3):471-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/17720528/pubmed\" target=\"_blank\" id=\"17720528\">17720528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leijn E, Monnens LA, and Cornelissen EA, &quot;Intravenous Iron Supplementation in Children on Hemodialysis,&quot; <i>J Nephrol</i>, 2004, 17(3):423-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/15365964/pubmed\" target=\"_blank\" id=\"15365964\">15365964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacKay M, Rusho W, Jackson D, et al, &quot;Physical and Chemical Stability of Iron Sucrose in Parenteral Nutrition,&quot; <i>Nutr Clin Pract</i>, 2009, 24(6):733-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/19955552/pubmed\" target=\"_blank\" id=\"19955552\">19955552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyer MP, Haworth C, Meyer JH, Commerford A. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. <i>J Pediatr</i>. 1996;129(2):258-263.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/8765624/pubmed\" target=\"_blank\" id=\"8765624\">8765624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norman JL and Crill CM, &quot;Optimizing the Transition to Home Parenteral Nutrition in Pediatric Patients,&quot; <i>Nutr Clin Pract</i>, 2011, 26(3):273-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/21586412/pubmed\" target=\"_blank\" id=\"21586412\">21586412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pinsk V, Levy J, Moser A, et al, &quot;Efficacy and Safety of Intravenous Iron Sucrose Therapy in a Group of Children With Iron Deficiency Anemia,&quot;<i> Isr Med Assoc J</i>, 2008, 10(5):335-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/18605353/pubmed\" target=\"_blank\" id=\"18605353\">18605353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollak A, Hayde M, Hayn M, et al, &quot;Effect of Intravenous Iron Supplementation on Erythropoiesis in Erythropoietin-Treated Premature Infants,&quot; <i>Pediatrics</i>, 2001, 107(1):78-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/11134438/pubmed\" target=\"_blank\" id=\"11134438\">11134438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollak A, Widness JA, and Lombard KA, &ldquo;Iron Supplementation During Erythropoietin Treatment,&rdquo; <i>Pediatrics</i>, 2001, 108(6): 1390-1.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rottembourg J, Kadri A, Leonard E, et al, &quot;Do Two Intravenous Iron Sucrose Preparations Have the Same Efficacy?&quot; <i>Nephrol Dial Transplant</i>, 2011, 26(10):3262-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/21355067/pubmed\" target=\"_blank\" id=\"21355067\">21355067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stein J, Dignass A, and Chow KU, &quot;Clinical Case Reports Raise Doubts About the Therapeutic Equivalence of an Iron Sucrose Similar Preparation Compared With Iron Sucrose Originator,&quot; <i>Curr Med Res Opin</i>, 2012, 28(2):241-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-pediatric-drug-information/abstract-text/22181342/pubmed\" target=\"_blank\" id=\"22181342\">22181342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venofer (iron sucrose) [prescribing information]. Shirley, NY: American Regent, Inc; November 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13058 Version 119.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F184604\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F184605\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1020337\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F15852436\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1020366\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F184587\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F184573\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963477\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1020369\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F184600\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1020338\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7897706\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F184624\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F184593\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F184577\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26023252\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299545\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F184581\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F184583\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F184594\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1020371\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1020360\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F184576\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F184592\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F5275404\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323230\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F184595\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13058|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iron-sucrose-drug-information\" class=\"drug drug_general\">Iron sucrose: Drug information</a></li><li><a href=\"topic.htm?path=iron-sucrose-patient-drug-information\" class=\"drug drug_patient\">Iron sucrose: Patient drug information</a></li></ul></div></div>","javascript":null}